FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909939544> ?p ?o ?g. }

• W2909939544 endingPage "3286" @default.
• W2909939544 startingPage "3286" @default.
• W2909939544 abstract "Abstract BACKGROUND The combination of pomalidomide (POM) and dexamethasone (DEX) for the treatment (Tx) of relapsed or refractory multiple myeloma (RRMM) in patients (pts) who have received ≥ 2 prior Tx regimens, including lenalidomide (LEN) and bortezomib (BORT), was approved in Europe in August 2013. POM-DEX is now a standard Tx for pts with RRMM. These pts are at an increased risk for adverse events (AEs) due to prior exposure to multiple lines of Tx and a high disease burden. The European Union post-authorization safety study (EU PASS; NCT02164955) is a prospective, observational, non-interventional study (method: registry) designed to characterize the safety profile of POM-based Tx in pts with RRMM in a real-world setting. AIM To report the incidence of key AEs with POM-based Tx, such as neutropenia, thrombocytopenia, venous thromboembolism (VTE), peripheral neuropathy (PN), and second primary malignancies (SPMs), in pts with RRMM treated with POM according to the last prior Tx before starting POM Tx in a post-marketing setting. METHODS Pts with symptomatic RRMM initiating POM-based Tx were enrolled at the investigator's discretion. Thromboprophylaxis was administered per local standard practice. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (v4.0). The study is ongoing and open for recruitment in centers across Europe. This analysis focused on the safety profile according to the last prior Tx received before starting POM Tx. RESULTS As of July 12, 2018, 596 pts across 100 institutions in 8 European countries were included in the safety population. At the time of data cutoff, Tx was ongoing in 122 pts (20.5%). Median age was 70 yrs (range, 37-92 yrs), with 28.4% of pts aged < 65 yrs, 38.4% between age 65 and 75 yrs, and 33.2% aged ≥ 75 yrs; 54.2% were male. Median time from diagnosis was 4.8 yrs (range, 0.3-26.9 yrs). Median number of prior Txs was 3; 72.1% of pts had ≥ 3 prior lines. Most pts received prior LEN (99.2%) and BORT (99.0%). In 343 pts assessed for Eastern Cooperative Oncology Group performance status (PS), 277 had a PS of 0 or 1 at baseline. Among 595 pts whose prior Tx was entered into the database at the time of data cutoff, the last prior Tx before starting POM was LEN in 340 pts (57.1%), BORT in 134 pts (22.5%), a combination of LEN and BORT in 16 pts (2.7%), and any other drug in 105 pts (17.6%). Tx duration of POM was slightly longer in pts treated with prior BORT than in those treated with prior LEN, with a median Tx duration of 18.7 wks (range, 0.9-150.0 wks) in the LEN group vs 23.7 wks (range, 0.1-148.0 wks) in the BORT group. Across all subgroups, hematologic AEs and infections represented most of all AEs (Table). CONCLUSIONS This ongoing, prospective, non-interventional study in pts with RRMM continues to demonstrate that POM-based Tx is generally well tolerated in the real-world setting and that the safety profile is not impacted by the Tx administered immediately before starting a POM-based Tx. Of all pts included in this trial, more pts were treated with LEN immediately before starting POM than any other drug. This analysis shows that AEs are almost similar in pts treated with LEN or BORT or both or any other drug immediately before starting POM Tx. In addition, the reported VTEs, PNs, and SPMs were generally low in all subgroups. Updated data will be presented at the meeting. Table. Table. Disclosures Abildgaard: Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding. Di Raimondo:Celgene: Honoraria; Takeda: Honoraria, Research Funding. Kueenburg:Celgene Corporation: Consultancy, Honoraria. Rosettani:Celgene International: Employment, Equity Ownership. Bacon:Celgene: Employment. Atiba-Davies:Celgene Corporation: Employment, Equity Ownership. Plesner:Janssen: Consultancy; Celgene: Other: Independent Response Assessment Comittee." @default.
• W2909939544 created "2019-01-25" @default.
• W2909939544 creator A5005958406 @default.
• W2909939544 creator A5008931161 @default.
• W2909939544 creator A5028707750 @default.
• W2909939544 creator A5029726728 @default.
• W2909939544 creator A5034393745 @default.
• W2909939544 creator A5039857929 @default.
• W2909939544 creator A5043530313 @default.
• W2909939544 creator A5051231544 @default.
• W2909939544 creator A5060699933 @default.
• W2909939544 creator A5061550633 @default.
• W2909939544 creator A5071261900 @default.
• W2909939544 creator A5089250078 @default.
• W2909939544 creator A5091097620 @default.
• W2909939544 date "2018-11-29" @default.
• W2909939544 modified "2023-09-26" @default.
• W2909939544 title "Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study" @default.
• W2909939544 doi "https://doi.org/10.1182/blood-2018-99-111906" @default.
• W2909939544 hasPublicationYear "2018" @default.
• W2909939544 type Work @default.
• W2909939544 sameAs 2909939544 @default.
• W2909939544 citedByCount "0" @default.
• W2909939544 crossrefType "journal-article" @default.
• W2909939544 hasAuthorship W2909939544A5005958406 @default.
• W2909939544 hasAuthorship W2909939544A5008931161 @default.
• W2909939544 hasAuthorship W2909939544A5028707750 @default.
• W2909939544 hasAuthorship W2909939544A5029726728 @default.
• W2909939544 hasAuthorship W2909939544A5034393745 @default.
• W2909939544 hasAuthorship W2909939544A5039857929 @default.
• W2909939544 hasAuthorship W2909939544A5043530313 @default.
• W2909939544 hasAuthorship W2909939544A5051231544 @default.
• W2909939544 hasAuthorship W2909939544A5060699933 @default.
• W2909939544 hasAuthorship W2909939544A5061550633 @default.
• W2909939544 hasAuthorship W2909939544A5071261900 @default.
• W2909939544 hasAuthorship W2909939544A5089250078 @default.
• W2909939544 hasAuthorship W2909939544A5091097620 @default.
• W2909939544 hasBestOaLocation W29099395441 @default.
• W2909939544 hasConcept C105639569 @default.
• W2909939544 hasConcept C126322002 @default.
• W2909939544 hasConcept C141071460 @default.
• W2909939544 hasConcept C143998085 @default.
• W2909939544 hasConcept C144133560 @default.
• W2909939544 hasConcept C197934379 @default.
• W2909939544 hasConcept C2776063141 @default.
• W2909939544 hasConcept C2776364478 @default.
• W2909939544 hasConcept C2776694085 @default.
• W2909939544 hasConcept C2777063308 @default.
• W2909939544 hasConcept C2777478702 @default.
• W2909939544 hasConcept C2777793932 @default.
• W2909939544 hasConcept C2778375690 @default.
• W2909939544 hasConcept C2778524551 @default.
• W2909939544 hasConcept C2778850193 @default.
• W2909939544 hasConcept C2909597000 @default.
• W2909939544 hasConcept C2910001868 @default.
• W2909939544 hasConcept C71924100 @default.
• W2909939544 hasConceptScore W2909939544C105639569 @default.
• W2909939544 hasConceptScore W2909939544C126322002 @default.
• W2909939544 hasConceptScore W2909939544C141071460 @default.
• W2909939544 hasConceptScore W2909939544C143998085 @default.
• W2909939544 hasConceptScore W2909939544C144133560 @default.
• W2909939544 hasConceptScore W2909939544C197934379 @default.
• W2909939544 hasConceptScore W2909939544C2776063141 @default.
• W2909939544 hasConceptScore W2909939544C2776364478 @default.
• W2909939544 hasConceptScore W2909939544C2776694085 @default.
• W2909939544 hasConceptScore W2909939544C2777063308 @default.
• W2909939544 hasConceptScore W2909939544C2777478702 @default.
• W2909939544 hasConceptScore W2909939544C2777793932 @default.
• W2909939544 hasConceptScore W2909939544C2778375690 @default.
• W2909939544 hasConceptScore W2909939544C2778524551 @default.
• W2909939544 hasConceptScore W2909939544C2778850193 @default.
• W2909939544 hasConceptScore W2909939544C2909597000 @default.
• W2909939544 hasConceptScore W2909939544C2910001868 @default.
• W2909939544 hasConceptScore W2909939544C71924100 @default.
• W2909939544 hasIssue "Supplement 1" @default.
• W2909939544 hasLocation W29099395441 @default.
• W2909939544 hasOpenAccess W2909939544 @default.
• W2909939544 hasPrimaryLocation W29099395441 @default.
• W2909939544 hasRelatedWork W1833952634 @default.
• W2909939544 hasRelatedWork W2036942759 @default.
• W2909939544 hasRelatedWork W2128903704 @default.
• W2909939544 hasRelatedWork W2400769328 @default.
• W2909939544 hasRelatedWork W2403269090 @default.
• W2909939544 hasRelatedWork W2792859185 @default.
• W2909939544 hasRelatedWork W2806380367 @default.
• W2909939544 hasRelatedWork W2902287712 @default.
• W2909939544 hasRelatedWork W2909939544 @default.
• W2909939544 hasRelatedWork W2917108915 @default.
• W2909939544 hasVolume "132" @default.
• W2909939544 isParatext "false" @default.
• W2909939544 isRetracted "false" @default.
• W2909939544 magId "2909939544" @default.
• W2909939544 workType "article" @default.